Clinical Cancer Research 2017 September [Epub ahead of print][Link] Zauderer MG, et.al. Abstract PURPOSE: Determine the 1-year progression-free survival (PFS) among patients with malignant pleural mesothelioma (MPM) receiving the WT1 peptide vaccine galinpepimut-S after multimodality therapy vs those receiving control adjuvants. PATIENTS AND METHODS: This double-blind, controlled, two center phase II trial randomized MPM patients…

Read More

Cancer Medicine 2017 September [Epub ahead of print] [Link] Zucali PA, Lopci E, Ceresoli GL, Giordano L, Perrino M, Ciocia G, Gianoncelli L, Lorenzi E, Simonelli M, De Vincenzo F, Setti LR, Bonifacio C, Bonomi M, Bombardieri E, Chiti A, Santoro A Abstract The aim of this study was to evaluate the role of metabolic…

Read More

Annals of Oncology 2017 September [Epub ahead of print] [Link] Giovannetti E, Zucali PA, Assaraf YG, Funel N, Gemelli M, Stark M, Thunnissen E, Hou Z, Muller IB, Struijs EA, Perrino M, Jansen G, Matherly LH, Peters GJ Abstract BACKGROUND: Thymidylate synthase (TS) has a predictive role in pemetrexed-treatment of mesothelioma, however additional chemoresistance mechanisms…

Read More

Thoracic Cancer 2013 February [Link] Okamoto T, Yano T, Haro A, Yoshida T, Kohno M, Maehara Y Abstract BACKGROUND:   Malignant pleural mesothelioma (MPM) is a relatively rare, aggressive neoplasm associated with asbestos exposure. Extrapleural pneumonectomy (EPP) is often performed for resectable MPM as part of a multidisciplinary treatment; however, available data on treatments for…

Read More

Cancer. 2017 September 18 [Epub ahead of print] [Link] Mansour MSI, Seidal T, Mager U, Baigi A, Dobra K, Dejmek A Abstract BACKGROUND: Malignant mesothelioma (MM) is an aggressive, fatal tumor. Current therapeutic options only marginally improve survival. Programmed cell death ligand 1 (PD-L1) is a dominant mediator of immunosuppression, binding to programmed cell death…

Read More

Histopathology 2017 September [Epub ahead of print] [Link] Chou A1, Toon CW1, Clarkson A1, Sheen A, Sioson L1 Gill AJ Abstract AIMS: Mesothelioma is a relatively uncommon but highly malignant neoplasm. Most patients die of disease within one year of diagnosis, but some have prolonged survival. Prospective identification of these longer-term survivors may help guide…

Read More

Reports of Practical Oncology and Radiotherapy 2017 September [Epub 2017 August 11] [Link] Harrabi SB, Koerber SA, Adeberg S, Katayama S, Herfarth K, Debus J, Sterzing F Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare and aggressive disease that poses a treatment challenge in spite of recent technical developments. The aim of this retrospective…

Read More

Asian Pacific Journal of Cancer Prevention 2017 August [Link] Rahouma M, Aziz H, Ghaly G, Kamel M, Loai I, Mohamed A Abstract Purpose: Malignant pleural mesothelioma (MPM) has a poor prognosis in general. Here we sought to evaluate prognostic factors and predictors of response to chemotherapy in good performance (PS=0-I) patients. Methods: We retrospectively reviewed…

Read More

Journal of Thoracic Oncology 2017 August 23 [Epub ahead of print] [Link] Verma V, Ahern CA, Berlind CG, Lindsay WD, Sharma S, Shabason J, Culligan MJ, Grover S, Friedberg JS, Simone CB Abstract INTRODUCTION: Controversy exists regarding the optimal surgical technique for malignant pleural mesothelioma (MPM). We evaluated national practice patterns and outcomes of MPM…

Read More